肿瘤预防与治疗
腫瘤預防與治療
종류예방여치료
JOURNAL OF CANCER CONTROL AND TREATMENT
2014年
3期
130-133
,共4页
张容榕%林琳%刘爱学%冯天举
張容榕%林琳%劉愛學%馮天舉
장용용%림림%류애학%풍천거
广泛期%小细胞肺癌%伊立替康%VP-16%顺铂%近期疗效%毒副反应
廣汎期%小細胞肺癌%伊立替康%VP-16%順鉑%近期療效%毒副反應
엄범기%소세포폐암%이립체강%VP-16%순박%근기료효%독부반응
Extensive Stage%Small-cell Lung Cancer%Irinotecan%VP-16%Cisplatin%Curative Effect%Adverse Effect
目的：比较两种不同化疗方案治疗广泛期小细胞肺癌的临床疗效及毒副反应。方法：回顾性分析2010年1月至2013年1月,我院肿瘤科住院治疗的70例广泛期小细胞肺癌患者的临床资料,分为伊立替康( IP)组和VP-16(EP)组,每组各35例患者,其中伊立替康组患者采用伊立替康联合顺铂方案化疗, VP-16组患者采用VP-16联合顺铂方案化疗,观察两组方案治疗患者的近期临床效果和毒副反应情况。结果：伊立替康( IP)组和VP-16(EP)组患者的有效率分别为74．28%(26/35)和71．42%(25/35),两组比较差异无统计学意义(P>0．05)；无进展生存期分别是4．3个月和3．7个月( P>0．05),总生存期分别是9．3个月和8．9个月( P>0．05)。伊立替康( IP)组的主要不良反应是粒细胞减少、血小板减少、贫血、腹泻、消化道反应,发生率分别为54．29%、14．29%、25．71%、22．86%、71．43%,VP-16(EP)组的主要不良反应反应为粒细胞减少、血小板减少、贫血、腹泻、消化道反应,发生率分别是80．0%、60．0%、54．29%、2．86%、74．29%。结论：IP和EP方案一线治疗广泛期小细胞肺癌的疗效和生存期无显著差异,不良反应均可耐受。
目的：比較兩種不同化療方案治療廣汎期小細胞肺癌的臨床療效及毒副反應。方法：迴顧性分析2010年1月至2013年1月,我院腫瘤科住院治療的70例廣汎期小細胞肺癌患者的臨床資料,分為伊立替康( IP)組和VP-16(EP)組,每組各35例患者,其中伊立替康組患者採用伊立替康聯閤順鉑方案化療, VP-16組患者採用VP-16聯閤順鉑方案化療,觀察兩組方案治療患者的近期臨床效果和毒副反應情況。結果：伊立替康( IP)組和VP-16(EP)組患者的有效率分彆為74．28%(26/35)和71．42%(25/35),兩組比較差異無統計學意義(P>0．05)；無進展生存期分彆是4．3箇月和3．7箇月( P>0．05),總生存期分彆是9．3箇月和8．9箇月( P>0．05)。伊立替康( IP)組的主要不良反應是粒細胞減少、血小闆減少、貧血、腹瀉、消化道反應,髮生率分彆為54．29%、14．29%、25．71%、22．86%、71．43%,VP-16(EP)組的主要不良反應反應為粒細胞減少、血小闆減少、貧血、腹瀉、消化道反應,髮生率分彆是80．0%、60．0%、54．29%、2．86%、74．29%。結論：IP和EP方案一線治療廣汎期小細胞肺癌的療效和生存期無顯著差異,不良反應均可耐受。
목적：비교량충불동화료방안치료엄범기소세포폐암적림상료효급독부반응。방법：회고성분석2010년1월지2013년1월,아원종류과주원치료적70례엄범기소세포폐암환자적림상자료,분위이립체강( IP)조화VP-16(EP)조,매조각35례환자,기중이립체강조환자채용이립체강연합순박방안화료, VP-16조환자채용VP-16연합순박방안화료,관찰량조방안치료환자적근기림상효과화독부반응정황。결과：이립체강( IP)조화VP-16(EP)조환자적유효솔분별위74．28%(26/35)화71．42%(25/35),량조비교차이무통계학의의(P>0．05)；무진전생존기분별시4．3개월화3．7개월( P>0．05),총생존기분별시9．3개월화8．9개월( P>0．05)。이립체강( IP)조적주요불량반응시립세포감소、혈소판감소、빈혈、복사、소화도반응,발생솔분별위54．29%、14．29%、25．71%、22．86%、71．43%,VP-16(EP)조적주요불량반응반응위립세포감소、혈소판감소、빈혈、복사、소화도반응,발생솔분별시80．0%、60．0%、54．29%、2．86%、74．29%。결론：IP화EP방안일선치료엄범기소세포폐암적료효화생존기무현저차이,불량반응균가내수。
Objective: To compare and analyze the efficacy and safety of two different treatment schema in previ-ously untreated extensive small-cell lung cancer. Methods:Seventy cases of patients with extensive small-cell lung cancer treated in the Oncology Department of our hospital from January 2010 to January 2013 were randomly assigned into irinote-can group( IP group,35 cases) and VP-16 group( EP group,35 cases) by random number table . Patients in IP group were treated with irinotecan and cisplatin(IP)and in EP group were treated with VP-16 and cisplatin(EP). The treatment re-sponse was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1. 1). Patients were assessed for toxicity according to WHO criteria for adverse events. Results:The objective response rates( RR) of IP group and EP group were 74. 28% and 71. 42%,respectively(P>0. 05). The median progression-free survival(PFS) for IP group and EP group were 4. 3 and 3. 7 months respectively(P>0. 05). The overall survival(OS) for IP group and EP group was 9. 3 and 8. 9 months,respectively(P>0. 05). The common adverse effects of IP group inclucled neutropenia(54. 29%),throm-bocytopenia(14. 29%),anemia(25. 71%),diarrhea(22. 86%)and nausea(71. 43%). The common adverse effects of EP group included neutropenia(80. 0%),thrombocytopenia(60. 0%),anemia(54. 29%),diarrhea(2. 86%)and nausea(74. 29%) . Conclusion:The study shows that there is no significant difference with the efficacy and survival of IP and EP regi-men as the first-line therapy for extensive small-cell lung cancer and the adverse effects are tolerant.
